• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»tumor infiltrating lymphocyte therapy

Obsidian Therapeutics puts OBX-115 in the spotlight, but is this a real melanoma cell therapy inflection point?

By Pallavi Madhiraju on April 22, 2026   Pharma & Biotech  

Obsidian Therapeutics puts OBX-115 in the spotlight, but is this a real melanoma cell therapy inflection point?

Obsidian Therapeutics will present OBX-115 melanoma data at ASCO 2026. Read why the update matters for TIL therapy, scalability, and solid tumor strategy.

Recent Posts

  • What TG Therapeutics, Inc.’s AAN 2026 updates reveal about real-world performance of BRIUMVI in multiple sclerosis
  • Why CervoMed Inc.’s neflamapimod findings may reshape biomarker-driven trials in dementia with Lewy bodies
  • Can Neurona Therapeutics validate regenerative cell therapy in epilepsy with Phase 3 EPIC trial
  • What Tempest Therapeutics, Inc.’s CAR-T strategy reveals about the next phase of cell therapy competition
  • Can CARTOSOUND SONATA help Johnson & Johnson tighten its grip on electrophysiology workflow?
  • Why Star Therapeutics’ FDA win for VGA039 could reshape the von Willebrand disease treatment race.
  • Can Alto Neuroscience turn an overlooked Parkinson’s drug into a major depression breakthrough?
  • Artera’s EU breakthrough in AI cancer testing opens a bigger battle over workflow, trust, and scale
  • Can Forlong Biotechnology’s FL115 poster at ASCO 2026 move the IL-15 story from scientific promise toward clinical relevance?
  • Incyte brings Phase 3 tafasitamab data to ASCO 2026, but will frontMIND reshape first-line DLBCL treatment?
  • Obsidian Therapeutics puts OBX-115 in the spotlight, but is this a real melanoma cell therapy inflection point?
  • Is botensilimab finally ready for a bigger melanoma spotlight? Agenus bets on ASCO 2026
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes